NCT04831437View on ClinicalTrials.gov

Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2028

Conditions
Cervix Uteri Cancer
Interventions
RADIATION

Hypofractionated EBRT

EBRT dose of 40Gy in 15 fractions over 3 weeks plus 3 weekly infusions of cisplatin 40mg/m2

RADIATION

Standard EBRT

EBRT dose of 45Gy in 25 fractions over 5 weeks plus 5 weekly infusions of cisplatin 40mg/m2

Trial Locations (1)

1419733141

RECRUITING

Imam Khomeini Hospital Complex, Tehran

All Listed Sponsors
lead

Tehran University of Medical Sciences

OTHER